KR20220082803A - (r)-n-(5-(5-이소프로필-1,2,4-옥사디아졸-3-일)-2,3-디하이드로-1h-인덴-1-일)-2-메틸-2h-테트라졸-5-카르복사미드의 다형체들 - Google Patents

(r)-n-(5-(5-이소프로필-1,2,4-옥사디아졸-3-일)-2,3-디하이드로-1h-인덴-1-일)-2-메틸-2h-테트라졸-5-카르복사미드의 다형체들 Download PDF

Info

Publication number
KR20220082803A
KR20220082803A KR1020227002979A KR20227002979A KR20220082803A KR 20220082803 A KR20220082803 A KR 20220082803A KR 1020227002979 A KR1020227002979 A KR 1020227002979A KR 20227002979 A KR20227002979 A KR 20227002979A KR 20220082803 A KR20220082803 A KR 20220082803A
Authority
KR
South Korea
Prior art keywords
degrees
polymorph
disease
subject
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227002979A
Other languages
English (en)
Korean (ko)
Inventor
놀마 톰
데니스 안데르센
Original Assignee
싸이토키네틱스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 싸이토키네틱스, 인코포레이티드 filed Critical 싸이토키네틱스, 인코포레이티드
Publication of KR20220082803A publication Critical patent/KR20220082803A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020227002979A 2019-07-17 2020-07-16 (r)-n-(5-(5-이소프로필-1,2,4-옥사디아졸-3-일)-2,3-디하이드로-1h-인덴-1-일)-2-메틸-2h-테트라졸-5-카르복사미드의 다형체들 Ceased KR20220082803A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962875355P 2019-07-17 2019-07-17
US62/875,355 2019-07-17
PCT/US2020/042390 WO2021011809A1 (en) 2019-07-17 2020-07-16 Polymorphs of (r)-n-(5-(5-isopropyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-2-methyl-2h-tetrazole-5-carboxamide

Publications (1)

Publication Number Publication Date
KR20220082803A true KR20220082803A (ko) 2022-06-17

Family

ID=71995105

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227002979A Ceased KR20220082803A (ko) 2019-07-17 2020-07-16 (r)-n-(5-(5-이소프로필-1,2,4-옥사디아졸-3-일)-2,3-디하이드로-1h-인덴-1-일)-2-메틸-2h-테트라졸-5-카르복사미드의 다형체들

Country Status (16)

Country Link
US (1) US20220274969A1 (https=)
EP (1) EP3999181B1 (https=)
JP (1) JP2022542803A (https=)
KR (1) KR20220082803A (https=)
CN (1) CN114667283B (https=)
AU (1) AU2020315433A1 (https=)
BR (1) BR112022000523A2 (https=)
CA (1) CA3144974A1 (https=)
CL (1) CL2022000089A1 (https=)
ES (1) ES2982707T3 (https=)
IL (1) IL289881A (https=)
MX (1) MX2022000498A (https=)
NZ (1) NZ784931A (https=)
PH (1) PH12022550084A1 (https=)
TW (1) TW202116764A (https=)
WO (1) WO2021011809A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019144041A1 (en) 2018-01-19 2019-07-25 Cytokinetics, Inc. Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
JP7610985B2 (ja) 2018-06-26 2025-01-09 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
WO2024179422A1 (zh) * 2023-03-02 2024-09-06 苏州科睿思制药有限公司 Aficamten的共晶及其制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE552236T1 (de) * 2003-01-14 2012-04-15 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren zur behandlung von herzinsuffizienz
WO2007078815A2 (en) * 2005-12-16 2007-07-12 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
WO2019144041A1 (en) * 2018-01-19 2019-07-25 Cytokinetics, Inc. Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors

Also Published As

Publication number Publication date
US20220274969A1 (en) 2022-09-01
IL289881A (en) 2022-03-01
EP3999181B1 (en) 2024-05-29
CN114667283B (zh) 2023-12-26
CN114667283A (zh) 2022-06-24
AU2020315433A1 (en) 2022-03-03
JP2022542803A (ja) 2022-10-07
NZ784931A (en) 2025-03-28
PH12022550084A1 (en) 2023-04-12
ES2982707T3 (es) 2024-10-17
CA3144974A1 (en) 2021-01-21
EP3999181A1 (en) 2022-05-25
TW202116764A (zh) 2021-05-01
MX2022000498A (es) 2022-02-03
EP3999181C0 (en) 2024-05-29
WO2021011809A1 (en) 2021-01-21
BR112022000523A2 (pt) 2022-03-03
CL2022000089A1 (es) 2022-10-07

Similar Documents

Publication Publication Date Title
CN114555590B (zh) (r)-n-(5-(5-乙基-1,2,4-噁二唑-3-基)-2,3-二氢-1h-茚-1-基)-1-甲基-1h-吡唑-4-甲酰胺的多晶型物
KR20220082803A (ko) (r)-n-(5-(5-이소프로필-1,2,4-옥사디아졸-3-일)-2,3-디하이드로-1h-인덴-1-일)-2-메틸-2h-테트라졸-5-카르복사미드의 다형체들
JP7438148B2 (ja) 心臓サルコメア阻害剤
KR20220082804A (ko) 심장 근섬유분절 억제제 경구 제제들
CN119998292A (zh) 5-(3,4-二氟苄基)-8-((1r,4r)-4-甲基环己基)-6,9-二氧代基-2,5,8-三氮杂螺[3.5]壬烷-2-甲醛的结晶形式
RU2846046C2 (ru) Полиморфы (r)-n-(5-(5-этил-1,2,4,-оксадиазол-3-ил)-2,3-дигидро-1н-инден-1-ил)-1-метил-1н-пиразол-4-карбоксамида
HK40076616A (en) Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide
HK40121580A (en) Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide
HK40075684A (en) Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide
HK40111816A (zh) 多晶型物
HK40125944A (zh) 5-(3，4-二氟苄基)-8-((1r，4r)-4-甲基环己基)-6，9-二氧代基-2，5，8-三氮杂螺[3.5]壬烷-2-甲醛的结晶形式

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601